Biosenic (BIOS.BR) Stock Price

Biosenic Price

Euronext Brussels·CLOSED
0.00EUR+0.00 (+0.00 %)
Market closed

Revenue has compounded at 0.0% per year over the past 3 years to 1.00 M EUR. Biosenic's net margin stands at -1,292.5%, up from -1,414.0% several years earlier. Analysts set a median price target of 0.10 EUR, implying 5,000.0% above the current price. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.

Biosenic stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Biosenic over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Biosenic stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Biosenic's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Biosenic Stock Price History
DateBiosenic Price
8/20/20260.00 EUR
8/19/20260.00 EUR
8/18/20260.00 EUR
8/17/20260.00 EUR
8/14/20260.00 EUR
8/13/20260.00 EUR
8/12/20260.00 EUR
8/11/20260.00 EUR
8/10/20260.00 EUR
8/7/20260.00 EUR
8/6/20260.00 EUR
8/5/20260.00 EUR
8/4/20260.00 EUR
8/3/20260.00 EUR
7/30/20260.00 EUR
7/29/20260.00 EUR
7/28/20260.00 EUR
7/27/20260.00 EUR
7/24/20260.00 EUR
7/23/20260.00 EUR
7/22/20260.00 EUR
7/21/20260.00 EUR
7/20/20260.00 EUR
7/17/20260.00 EUR
7/16/20260.00 EUR
7/15/20260.00 EUR
7/14/20260.00 EUR
7/13/20260.00 EUR
7/10/20260.00 EUR
7/9/20260.00 EUR
7/8/20260.00 EUR
7/7/20260.00 EUR
7/6/20260.00 EUR
7/3/20260.00 EUR
7/2/20260.00 EUR
7/1/20260.00 EUR
6/30/20260.00 EUR
6/29/20260.00 EUR
6/26/20260.00 EUR
6/25/20260.00 EUR
6/24/20260.00 EUR
6/23/20260.00 EUR
6/22/20260.00 EUR
6/19/20260.00 EUR
6/18/20260.00 EUR
6/17/20260.00 EUR
6/16/20260.00 EUR
6/15/20260.00 EUR
6/12/20260.00 EUR
6/11/20260.00 EUR
6/10/20260.00 EUR
6/9/20260.00 EUR
6/8/20260.00 EUR
6/5/20260.00 EUR
6/4/20260.00 EUR
6/3/20260.00 EUR
6/2/20260.00 EUR
6/1/20260.00 EUR
5/29/20260.00 EUR
5/28/20260.00 EUR
5/27/20260.00 EUR
5/26/20260.00 EUR
5/25/20260.00 EUR
5/22/20260.00 EUR
5/21/20260.00 EUR
5/20/20260.00 EUR
5/19/20260.00 EUR
5/18/20260.00 EUR
5/15/20260.00 EUR
5/14/20260.00 EUR
5/13/20260.00 EUR
5/12/20260.00 EUR
5/11/20260.00 EUR
5/8/20260.00 EUR
5/7/20260.00 EUR
5/6/20260.00 EUR
5/5/20260.00 EUR
5/4/20260.00 EUR
4/30/20260.00 EUR
4/29/20260.00 EUR
4/28/20260.00 EUR
4/27/20260.00 EUR
4/24/20260.00 EUR
4/23/20260.00 EUR
4/22/20260.00 EUR
4/21/20260.00 EUR
4/20/20260.00 EUR
4/17/20260.00 EUR
4/16/20260.00 EUR
4/15/20260.00 EUR
4/14/20260.00 EUR
4/13/20260.00 EUR
4/10/20260.00 EUR
4/9/20260.00 EUR
4/8/20260.00 EUR
4/7/20260.00 EUR
4/2/20260.00 EUR
3/27/20260.00 EUR
3/26/20260.00 EUR
3/25/20260.00 EUR
3/24/20260.00 EUR
3/23/20260.00 EUR
3/20/20260.00 EUR
3/19/20260.00 EUR
3/18/20260.00 EUR
3/17/20260.00 EUR
3/16/20260.00 EUR
3/13/20260.00 EUR
3/12/20260.00 EUR
3/11/20260.00 EUR
3/10/20260.00 EUR
3/9/20260.00 EUR
3/6/20260.00 EUR
3/5/20260.00 EUR
2/26/20260.00 EUR
2/25/20260.00 EUR
2/24/20260.00 EUR
2/23/20260.00 EUR
2/20/20260.00 EUR
2/19/20260.00 EUR
2/18/20260.00 EUR
2/17/20260.00 EUR
2/16/20260.00 EUR
2/13/20260.00 EUR
2/12/20260.00 EUR
2/11/20260.00 EUR
2/10/20260.00 EUR
2/9/20260.00 EUR
2/6/20260.00 EUR
2/5/20260.00 EUR
2/4/20260.00 EUR
2/3/20260.00 EUR
2/2/20260.00 EUR
1/30/20260.00 EUR
1/29/20260.00 EUR
1/28/20260.00 EUR
1/27/20260.00 EUR
1/26/20260.00 EUR
1/23/20260.00 EUR
1/22/20260.00 EUR
1/21/20260.00 EUR
1/20/20260.00 EUR
1/19/20260.00 EUR
1/16/20260.00 EUR
1/15/20260.00 EUR
1/14/20260.00 EUR
1/13/20260.00 EUR
1/12/20260.00 EUR
1/9/20260.00 EUR
1/8/20260.00 EUR
1/7/20260.00 EUR
1/6/20260.00 EUR
1/5/20260.00 EUR
1/2/20260.00 EUR
12/31/20250.00 EUR
12/30/20250.00 EUR
12/29/20250.00 EUR
12/24/20250.00 EUR
12/23/20250.00 EUR
12/22/20250.00 EUR
12/19/20250.00 EUR
12/18/20250.00 EUR
12/17/20250.00 EUR
12/16/20250.00 EUR
12/15/20250.00 EUR
12/12/20250.00 EUR
12/11/20250.00 EUR
12/10/20250.00 EUR
12/9/20250.00 EUR
12/8/20250.00 EUR
12/5/20250.00 EUR
12/4/20250.00 EUR
12/3/20250.00 EUR
12/2/20250.00 EUR
12/1/20250.00 EUR
11/28/20250.00 EUR
11/27/20250.00 EUR
11/26/20250.00 EUR
11/25/20250.00 EUR
11/24/20250.00 EUR
11/21/20250.00 EUR
11/20/20250.00 EUR
11/19/20250.00 EUR
11/18/20250.00 EUR
11/17/20250.00 EUR
11/14/20250.00 EUR
11/13/20250.00 EUR
11/12/20250.00 EUR
11/11/20250.00 EUR
11/10/20250.00 EUR
11/7/20250.00 EUR
11/6/20250.00 EUR
11/5/20250.00 EUR
11/4/20250.00 EUR
11/3/20250.00 EUR
10/31/20250.00 EUR
10/30/20250.00 EUR
10/29/20250.00 EUR
10/28/20250.00 EUR
10/27/20250.00 EUR
10/24/20250.00 EUR
10/23/20250.00 EUR
10/22/20250.00 EUR
10/21/20250.00 EUR
10/20/20250.00 EUR
10/17/20250.00 EUR
10/16/20250.00 EUR
10/15/20250.00 EUR
10/14/20250.00 EUR
10/13/20250.00 EUR
10/10/20250.00 EUR
10/9/20250.00 EUR
10/8/20250.00 EUR
10/7/20250.00 EUR
10/6/20250.00 EUR
10/3/20250.00 EUR
10/2/20250.00 EUR
10/1/20250.00 EUR
9/30/20250.00 EUR
9/29/20250.00 EUR
9/26/20250.00 EUR
9/25/20250.00 EUR
9/24/20250.00 EUR
9/23/20250.00 EUR
9/22/20250.00 EUR
9/19/20250.00 EUR
9/18/20250.00 EUR
9/17/20250.00 EUR
9/16/20250.00 EUR
9/15/20250.00 EUR
9/12/20250.00 EUR
9/11/20250.00 EUR
9/10/20250.00 EUR
9/9/20250.00 EUR
9/8/20250.00 EUR
9/5/20250.00 EUR
9/4/20250.00 EUR
9/3/20250.00 EUR
9/2/20250.00 EUR
9/1/20250.00 EUR
8/29/20250.00 EUR
8/28/20250.00 EUR
8/27/20250.00 EUR
8/26/20250.00 EUR
8/25/20250.00 EUR
Access this data via the Eulerpool API
Get Free API Key

Biosenic Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
1.00 M EUR
-11.47 M EUR
-14.14 M EUR
Jan 1, 2019
0.00 EUR
-7.95 M EUR
-7.52 M EUR
Jan 1, 2020
1.00 M EUR
-15.02 M EUR
-11.94 M EUR
Jan 1, 2021
1.00 M EUR
-12.03 M EUR
-12.93 M EUR
Jan 1, 2022
0.00 EUR
-2.32 M EUR
-2.04 M EUR
Jan 1, 2023
0.00 EUR
-7.00 M EUR
-29.00 M EUR
Jan 1, 2024
0.00 EUR
-5.21 M EUR
-4.77 M EUR

Biosenic Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 22, 2026, 5:19 PM
 
REVENUEk EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2018201920202021202220232024
1,000.00–1,000.001,000.00–––
-11.00-7.00-15.00-12.00-2.00-7.00-5.00
-1,100.00–-1,500.00-1,200.00–––
-14.00-7.00-11.00-12.00-2.00-29.00-4.00
–-50.0057.149.09-83.331,350.00-86.21
7.619.5411.7216.86120.13137.00231.00
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Biosenic generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Biosenic retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Biosenic's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Biosenic has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Biosenic's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Biosenic stock margins

The Biosenic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biosenic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biosenic.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
0.00 %
-1,147.00 %
-1,414.00 %
Jan 1, 2019
0.00 %
- %
- %
Jan 1, 2020
0.00 %
-1,501.70 %
-1,194.00 %
Jan 1, 2021
0.00 %
-1,202.60 %
-1,292.50 %
Jan 1, 2022
0.00 %
- %
- %
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %

Biosenic Stock Revenue, EBIT, Earnings per Share

The Biosenic earnings per share therefore indicates how much revenue Biosenic has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.13 EUR
-1.51 EUR
-1.86 EUR
Jan 1, 2019
0.00 EUR
-0.83 EUR
-0.79 EUR
Jan 1, 2020
0.09 EUR
-1.28 EUR
-1.02 EUR
Jan 1, 2021
0.06 EUR
-0.71 EUR
-0.77 EUR
Jan 1, 2022
0.00 EUR
-0.02 EUR
-0.02 EUR
Jan 1, 2023
0.00 EUR
-0.05 EUR
-0.21 EUR
Jan 1, 2024
0.00 EUR
-0.02 EUR
-0.02 EUR

Biosenic business model & stock analysis

Bone Therapeutics SA is a Belgian company specializing in the development of innovative therapies for bone and joint diseases. Its goal is to treat patients with severe orthopedic conditions and help improve their quality of life. The company's business model is based on extensive research and development strategies aimed at developing groundbreaking therapies for diseases such as fractures, osteoporosis, osteoarthritis, and other bone and joint-related conditions. It focuses on the development of innovative stem cell-based therapies that help repair damaged tissues and promote self-regeneration. Additionally, Bone Therapeutics has developed a special cell therapy called Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells, targeting cartilage growth as an alternative, cell-based therapy for knee and hip osteoarthritis. It has also developed a platform called Allogeneic Osteoblastic Cells, aiming to treat ligament and tendon injuries. The company conducts research and clinical studies in collaboration with academic partners to improve its therapies and develop new products and solutions. It operates in three business areas: Orthobiology, Cardiology, and Immunology, focusing on the development and marketing of therapies for bone and joint arthritis, cardiovascular diseases, and autoimmune diseases, respectively. Its current product offerings include Allob, AlgoScaff, and JTA-004 for the treatment of orthopedic conditions such as fractured vertebrae, severe bone injuries, bone regeneration, osteoporosis, and osteoarthritis. Bone Therapeutics is headquartered in Gosselies, Belgium, with offices in the US, France, Germany, and Italy. Its mission is to advance the development of therapies for bone and joint diseases and assist patients with severe orthopedic conditions. Through its research and development strategies, collaboration with academic partners, and strong market position, Bone Therapeutics aims to make a difference in the field.

Biosenic SWOT Analysis

Strengths

Bone Therapeutics SA has a strong portfolio of innovative products in the field of regenerative medicine, especially focused on orthopedics and bone related diseases. The company's advanced stem cell technology and expertise in cell therapy offer a unique competitive advantage.

The strong research and development capabilities of Bone Therapeutics SA enable the company to continually innovate and improve its product offerings. This positions them well for future growth and potential breakthroughs in the field.

Weaknesses

One weakness of Bone Therapeutics SA is its relatively small size compared to some of its competitors. This may limit their resources and ability to compete on a global scale.

The company also faces risks associated with the regulatory environment. Changes in regulations or delays in obtaining regulatory approvals could impact the company's ability to bring its products to market.

Opportunities

There are significant opportunities for Bone Therapeutics SA in the growing market for regenerative medicine. As the population ages and the incidence of orthopedic and bone-related conditions increases, there is a greater demand for innovative treatment options.

The company can also explore partnerships and collaborations to expand its reach and access new markets. By entering into strategic alliances with larger pharmaceutical companies or healthcare providers, Bone Therapeutics SA can leverage their resources and distribution channels.

Threats

One of the major threats facing Bone Therapeutics SA is competition. The field of regenerative medicine is highly competitive, with numerous companies vying for market share. Bone Therapeutics SA must continuously differentiate itself and stay ahead in terms of product development and innovation.

Economic factors and reimbursement policies can also pose threats to the company's success. Changes in healthcare spending, insurance coverage, or pricing pressures could impact the adoption and commercialization of Bone Therapeutics SA's products.

Biosenic Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Biosenic historical P/E ratio, EBIT multiple, and P/S ratio

Biosenic annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Biosenic shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
7.61 M Stocks
Jan 1, 2019
9.54 M Stocks
Jan 1, 2020
11.72 M Stocks
Jan 1, 2021
16.86 M Stocks
Jan 1, 2022
120.13 M Stocks
Jan 1, 2023
137.00 M Stocks
Jan 1, 2024
231.00 M Stocks

Current Biosenic forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
33.33 % (3)
Sell
66.67 % (6)
12M Price Target
0.10
Last Price
0.00
Currency
EUR
12M Return Potential
5,000.00 %
LTM Return
0 %

Biosenic shareholder structure

% Name
21.50984%
Vannineuse (Pierre)
Vannineuse (Pierre)
0.00000%
La Financière de l'Echiquier
La Financière de l'Echiquier

Biosenic Beneficial Ownership Filings (SEC 13D/G)

Free Float
92.4%
Float Shares
-
Shares Outstanding
-

Biosenic Executives and Management Board

12 members · avg. age 65 · 33 % women

FR

Mr. Francois Rieger (79)

Executive Chairman of the Board, Chief Executive Officer · since 2022

38,554.00 EUR

Management

VS

Ms. Veronique Pomi Schneiter (58)

Deputy Chief Executive Officer, Executive Director · since 2022

–

Board of Directors

CD

Dr. Claudia D'Augusta

Independent Director

30,000.00 EUR
DM

Mr. Damian Marron (63)

Independent Director

25,000.00 EUR
JP

Dr. Jean-Paul Prieels

Independent Director

25,000.00 EUR
GM

Dr. Gloria Matthews (52)

Independent Director

20,000.00 EUR
JV

Mr. Jeanluc Vandebroek

Non-Executive Director · since 2017

5,625.00 EUR
BS

Mr. Baron Stephenne (75)

Independent Director · since 2018

4,687.00 EUR

Frequently asked questions about Biosenic

The business model of Bone Therapeutics SA is focused on developing innovative cell therapy treatments for orthopedic conditions and bone diseases. Their approach involves the use of mesenchymal stromal cells (MSCs) derived from bone marrow, which have the potential to regenerate and repair damaged bone tissue. By harnessing the regenerative capabilities of MSCs, Bone Therapeutics aims to provide effective and safe solutions for patients suffering from debilitating bone disorders. This Belgian biotech company seeks to market their proprietary products globally, while conducting clinical trials and collaborating with scientific and medical communities to advance the field of cell therapy in orthopedics.

Bone Therapeutics SA is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Bone Therapeutics SA in the market include companies such as Medtronic PLC, Johnson & Johnson Services, Inc., Novartis AG, and Zimmer Biomet Holdings, Inc.

Bone Therapeutics SA is a Belgium-based biotechnology company specializing in the development of innovative regenerative therapies for orthopedic conditions. Founded in 2006, the company focuses on advanced cell-based therapies and biomaterials to support the healing process of bone and joint diseases. With a deep commitment to research and development, Bone Therapeutics aims to address unmet medical needs in areas such as osteoporosis, spinal fusion, and osteonecrosis. Leveraging their expertise in bone biology, Bone Therapeutics is dedicated to advancing the field of regenerative medicine and providing patients with effective and safe treatment options.

Bone Therapeutics SA, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed Phase I/II trials for its breakthrough product, ALLOB®, a unique cell therapy for bone disorders. Additionally, Bone Therapeutics SA received clearance from regulatory authorities to initiate a Phase III clinical study for its advanced ALLOB® therapy, further validating its safety and efficacy. Moreover, the company forged strategic collaborations with renowned institutions, including the Musculoskeletal Transplant Foundation and the Santé Clinical Research Center. These partnerships enable Bone Therapeutics SA to leverage the expertise and resources required to advance their innovative bone therapies and bring them to market efficiently.

Bone Therapeutics SA is primarily present in multiple countries and regions. Some of the key areas where the company operates include Europe, particularly Belgium (where it is headquartered), France, and Luxembourg. With a strong focus on regenerative medicine and developing innovative therapies for bone-related disorders, Bone Therapeutics SA has established a presence in these regions to facilitate its research, clinical trials, and commercialization efforts. By leveraging its expertise and collaborations, the company aims to provide novel treatment options for patients with orthopedic and bone diseases in these countries and beyond.

Bone Therapeutics SA is a leading biotechnology company committed to improving patients' lives by developing innovative treatments for orthopedic conditions and bone diseases. Guided by a strong corporate philosophy, Bone Therapeutics SA values scientific excellence, collaboration, and patient-centricity. The company aims to provide revolutionary therapies that harness the regenerative potential of bone for repairing and preventing bone-related problems. With a focus on translational medicine and cutting-edge research, Bone Therapeutics SA strives to deliver breakthrough solutions and improve the quality of life for patients suffering from musculoskeletal disorders.

Analysts currently set an average price target of 0.10 EUR for the Biosenic stock (median: 0.10 EUR), implying +5,000.0 % versus the latest price. The consensus is based on 9 analyst ratings.

Biosenic Analyst Price Targets 2026

9 analysts currently rate the Biosenic stock: 0 recommend buying, 3 holding and 6 selling.

Biosenic Analyst Price Targets 2026

The Biosenic share (BIOS.BR) is listed on 6 stock exchanges, including: Frankfurt (BT1.F), Düsseldorf (BT1.DU), London (0R55.L), London (0R55.L).

Bone Therapeutics SA is a biopharmaceutical company that specializes in the development of innovative cell therapies for bone and joint diseases. The company focuses on rapid market introduction of therapies based on selected and well-characterized cell types that provide clinically significant improvement. The company is divided into two business segments – bone and joint replacement products, and cell therapies. In the first segment, they offer products such as Artebone and Allob, which are aimed at replacing bone and joint tissue. Artebone is a natural bone matrix derived from bovine bone and regenerates into new bone through the body's own regeneration process. Allob, on the other hand, is an allogeneic bone marrow derivative obtained from human donor bones and is currently being tested in clinical trials for the treatment of bone defects and osteonecrosis. In the second business segment, Bone Therapeutics SA is developing cell therapies. They have two therapies in clinical development. Allob-MSC1 is an allogeneic combination of bone marrow-derived mesenchymal stromal cells (MSCs) and the aforementioned Allob product, which is used for the treatment of osteonecrosis. The product is currently in Phase III of clinical trials. JTA-004 is an injection consisting of leukocyte-derived mesenchymal stem cells (LMSCs) and is being developed for the treatment of knee osteoarthritis. The product has already been successfully tested in a Phase IIa study and is currently in Phase III of clinical trials. Bone Therapeutics SA works closely with academic and clinical partners and is building a network of collaborations to accelerate the development of cell therapies for orthopedic indications. The company has also entered into several licensing agreements with other companies to support its clinical trials with innovative techniques and products. Overall, Bone Therapeutics SA aims to take a leading position in the field of cell therapies for bone and joint diseases. The company has developed unique products and advanced technologies to address the clinical gaps in this area and bring significant improvements to patients. Bone Therapeutics SA strives for the rapid market introduction of its products and works hard to develop safer and more effective cell therapies for orthopedic indications.

The revenue cannot currently be calculated for Biosenic.

The profit cannot currently be calculated for Biosenic.

The P/E ratio cannot be calculated for Biosenic at the moment.

The P/S cannot be calculated for Biosenic currently.

The Eulerpool Quality Score for Biosenic is 2/10.

The ISIN of Biosenic is BE0974280126. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biosenic is A14NHV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biosenic is BIOS.BR. The ticker symbol is used to trade Biosenic shares on the stock exchange.

Biosenic paid dividends every year for the past 0 years.

Biosenic is assigned to the 'Health' sector.

The dividends of Biosenic are distributed in EUR.

All fundamentals and in-depth analysis of Biosenic

Our stock analysis for Biosenic stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biosenic. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Biosenic Stock
Biosenic Revenue→
Biosenic Stock
Biosenic Net Income→
Biosenic Stock
Biosenic P/E→
Biosenic Stock
Biosenic P/S→
Biosenic Stock
Biosenic EBIT→
Biosenic Stock
Biosenic Dividend→
Biosenic Stock
Biosenic Directors Dealings→
Biosenic Stock
Biosenic Stocks→
Biosenic Stock
Biosenic Market capitalization→
Biosenic Stock
Biosenic Debt→
Biosenic Stock
Biosenic Liabilities→
Biosenic Stock
Biosenic Equity→
Biosenic Stock
Biosenic AAQS→
Biosenic Stock
Biosenic Employees→
Biosenic Stock
Biosenic ROE→
Biosenic Stock
Biosenic ROA→
Biosenic Stock
Biosenic ROCE→
Biosenic Stock
Biosenic News→
Biosenic Stock
Biosenic Analyst Price Targets→

Health Stocks

BiosergenBioscience Animal Health PCLBiosino Bio-Technology and ScienceBioretec OyBiostar PharmaceuticalsBioRestorative TherapiesBiostaxBioray Biotech CoBiostem TechnologiesBiora TherapeuticsBioSyentBioqualAll Stocks A–Z →